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ORIGINAL RESEARCH
Hypothyroidism in coronary heart disease and
its relation to selected risk factors
Introduction: Hypothyroidism (HT) has been found a predictor of cardiovascular diseases.
We aimed to ascertain the prevalence of HT in patients with manifest coronary heart disease
(CHD), and to establish its association with conventional risk factors.
Methods: 410 patients, 6–24 months after hospitalization for acute coronary syndrome, and/or
revascularization, were included into the cross-sectional study.
Results: The prevalence of thyroid dysfunction was found in males and females as follows:
overt HT, ie, thyroid stimulating hormone (TSH) > 3.65 mIU/L and free thyroxine (fT4) < 9
pmol/L and/or L-thyroxine substitution, in 2.6% and 8.4%, respectively; subclinical HT (TSH
>3.65, fT4 9–23 and no substitution) in 4.3% and 15.0%, respectively. Higher prevalence of HT
was found in females with hypercholesterolemia, and in males and females with concomitant
positive thyroid peroxydase antibodies. Hypothyroid subjects had higher total homocysteine in
both genders and von Willebrand factor in males only. Hypothyroid females had higher total and
LDL cholesterol, and were more often treated for diabetes.
Conclusions: HT was found highly prevalent in patient with clinical coronary heart disease,
mainly in females, and was associated with several cardiovascular risk factors.
Keywords: hypothyroidism, coronary heart disease, cholesterol, homocysteine, diabetes.
Introduction
The association between overt hypothyroidism and coronary heart disease has been
repeatedly observed (Becker 1985). Less evident is the role of asymptomatic mild
elevation of thyroid stimulating hormone (subclinical hypothyroidism),
notwithstanding that it represents the majority of patients with thyroid dysfunction. It
was shown (Hak et al 2000) that even subclinical hypothyroidism independently
doubled relative risk of myocardial infarction in females. The most frequent cause of
hypothyroidism is the autoimmune thyroid disease (AITD) manifested by elevated
thyroid antibodies, namely thyroid peroxydase antibodies (Samuels 1998). Thus, a
sole increase in thyroid antibodies may potentially influence the coronary risk. The
aim of our study was to establish the prevalence of thyroid dysfunction in a well
defined sample of patients with manifest coronary heart disease and to assess its
associations with other coronary risk factors.
Methods
Study sample consisted of patients with clinically manifest coronary artery disease,
examined in the course of EuroAspire II survey, as Czech sample of this multinational
project, methods of selection and interview of these patients were described in details
elsewhere (EUROASPIRE II group 2001). Briefly, study sample selection was conducted
by review of 525 hospital medical records of patients hospitalized for acute coronary
event or coronary revascularization procedure. All responders were interviewed and
examined by standardized methods at minimum of 6 months and maximum of 2 years
after this hospitalization. Information on personal and demographic characteristics,
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personal and family history of coronary heart disease, life-
style, and current pharmacotherapy were obtained at
interview. The following standardized examinations were
performed. Height and weight were measured in light indoor
clothes without shoes using SECA 707 scales and measuring
stick. Waist and hip circumferences were measured using a
tape measure, and waist to hip ratio (WHR) was calculated.
Blood pressure (BP) was measured twice in the sitting
position on the right arm, using standard mercury
sphygmomanometers to the nearest 2 mm of mercury.
Information about reported current smoking was verified by
breath carbon monoxide measurement using Smokerlyser
device (model EC 50, Bedfont Scientific, Upchurch, UK).
Venous blood samples drawn in fasting state were used
for biochemical laboratory analysis. The laboratory
examinations included estimation of total (TCHOL) and HDL
cholesterol (HDL), triglycerides (TG), and glucose (GLU) and
were provided by the central laboratories of the EUROASPIRE
II study (University Department of Medicine, Manchester
Royal Infirmary, Manchester, UK). Unimate 7 cholesterol,
Unimate HDL Direct and Unimate triglyceride reagents
(Roche Diagnostics, Mannheim, Germany) on a Cobas Mira
S Autoanalyser (Roche Diagnostics) were used. During the
course of the study, the coefficient of variation for total
cholesterol was 1.2%, for HDL cholesterol 9.4%, and for
triglycerides 2.1%. Plasma glucose was measured from
lithium-heparin samples using the hexokinase method on a
Bayer Axon analyser (Bayer AG, Leverkusen, Germany);
coefficient of variation was 2.8%. Non-HDL cholesterol (non-
HDL) was calculated as difference between TCHOL and HDL.
Additional variables were estimated in our local laboratory
from serum aliquots series, stored at –80
0C. Thyroid
stimulating hormone (TSH), free thyroxine (fT4), thyroid
peroxydase antibodies (TPO-Ab), total homocysteine (tHcy),
folate, and vitamin B12 were assessed using commercial
fluorescent polarization immunoassay (FPIA) kits (Abbott
Laboratories, Wiesbaden, Germany) and AxSym analyser
(variations of these measurements were less than 1.5%).
Ultrasenzitive C-reactive protein (uCRP) was estimated
immunoturbidimetricaly using Orion Diagnostica (Espoo,
Finland) commercial kits and Olympus AU400 analyser
(coefficient of variation was 4.1%). Serum intracellular
adhesion molecule-1 (ICAM-1) and vascular adhesive
molecule-1 (VCAM-1) were assessed using ELISA by RD
Systems (Minneapolis, USA) and von Willebrand factor (vWf)
was assessed by IMTEC GmbH (Berlin, Germany) ELISA
kits; coefficients of variation of these ELISA analyses were
less than 9%. All procedures were done according to the Good
Clinical Practice regulation and were approved by the local
Ethical Committee. Informed consent was obtained from all
subjects and all personal data were stored under the provisions
of the Czech Data Protection Act.
Statistical analysis of the data was done using software
STATA Version 8 on PC. In the present study we categorized
the thyroid parameters by following definitions: euthyroid-
TSH 0.58–3.65 mIU/L. and fT4 9.0–23.0 pmol/L; overt
hypothyroidism—  TSH > 3.65 mIU/L and fT4 less than 9.0
pmol/L and/or thyroxine supplementation; subclinical
hypothyroidism—  TSH > 3.65 mIU/L and fT4 9.0–23.0 pmol/L;
hyperthyroidism—  TSH < 0.58 mIU/L. Positive TPO-Ab
(ie, autoimmune thyroid disorder) was defined as TPO-Ab >
14 IU/L. The reference ranges for TSH and TPO-Ab were given
for particular kits used, according to the methodology
described in National Academy of Clinical Biochemistry
guidelines (Baloch et al 2003): the TSH reference range was
established as 95% confidence limits of log-transformed TSH
of 120 healthy (60 males and 60 females), TPO-Ab negative
volunteers, aged less than 30 years, without personal or
family history of thyroid disorder or palpable goiter. Similarly,
TPO-Ab reference range was established from 120 male
healthy volunteers, aged less than 30 years, with TSH
concentrations between 0.5–2.0 mU/L, without palpable
goiter, personal or family history of thyroid disease or any
autoimmune disorder. The significance of differences among
hypothyroid and euthyroid subjects were evaluated by
Fisher’s χ
2 test for categorical variables and by Mann-
Whitney U test for continuous variables. Multiple logistic
regressions were used to ascertain the adjusted odds ratios
(OR) and 95% confidence intervals (CI).
Results
A total of 410 responders, aged 59.2 + 0.39 (age range 36.6–
73.8 years), 301 males and 109 females, were analyzed in the
present study. The overall distribution of TSH is shown
separately by gender in Figure 1. In females, the distribution
curve is skewed towards higher values, medians of values
(25th and 75th percentiles) for males and females were 1.52
(1.08, 2.07) and 1.74 (1.08, 2.99), respectively (p < 0.01;
Mann-Whitney U test). The prevalence of various forms of
thyroid disorder is given in Table 1. Prevalence of
hypothyroidism was significantly higher in females than in
males, and moreover, euthyroid females were more often TPO-
Ab positive, than euthyroid males. Hypothyroid females were
also more often substituted with thyroid hormones thanVascular Health and Risk Management 2006:2(4) 501
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males. We separately analyzed the prevalence and odds ratios
of overt or subclinical hypothyroidism in selected particular
subgroups (Table 2). Prevalence of hypothyroidism was more
than 3 times higher in subjects with TPO-Ab > 14 IU/L in
both genders and also significantly higher in females with
total cholesterol levels greater than 7 mmol/L.
We compared a large set of coronary risk factors by thyroid
status and presence of positive TPO-Ab (Table 3). As expected,
males and females with hypothyroidism (both, overt or
subclinical, but without L-thyroxine substitution) had
significantly higher TSH and TPO-Ab, while lower fT4
concentrations, than the euthyroid TPO-Ab negative subjects
(as can be expected). Hypothyroidism was associated with
increased tHcy in both genders and the significance of
association remained significant even after adjustement for
potential confounders (age, current smoking, fibrate
 Table 1 Prevalence of thyroid function categories in males and females with clinical coronary heart disease [n (%)]
Total sample Males Females p
All patients 410 303 107 -
Euthyroid 341 (83.2%) 265 (87.5%) 76 (71.0%) -
TPO-Ab negative 312 (76.1%) 252 (83.2%) 60 (56.0%) -
TPO-Ab positive 29 (7.1%) 13 (4.3%) 16 (15.0 %) <0.0001
b
Hypothyroid 46 (11.2%) 21 (6.9%) 25 (23.4%) <0.0001a
subclinical 29 (7.1%) 13 (4.3%) 16 (15.0%) -
overt untreated 9 (2.2%) 7 (2.3%) 2 (1.9%) -
overt treated 8 (1.9%) 1 (0.3%) 7 (6.5%) <0.03
b
Hyperthyroid
c 23 (5.6%) 17 (5.6%) 6 (5.6%) 0.67
a
agender differences in prevalence of hypo- or hyperthyroidism.
b gender differences in proportion of subcategories (χ
2 test).
covert or subclinical.
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Figure 1 Distribution of thyroid stimulating hormone concentrations in males and females with clinical coronary heart disease (left axis for frequency, right axis for
cumulative distribution).Vascular Health and Risk Management 2006:2(4) 502
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treatment, creatinine, folate, and B12 concentrations). Males
with hypothyroidism showed increased levels of vWf, and
again, the significance of this association also persisted, if
adjusted for potential confounders (age, current smoking,
systolic blood pressure, LDL-cholesterol, glucose, and tHcy
concentrations). On the other hand, the significance of
association between VCAM-1 and hypothyroidism
disappeared after adjustment for the same confounders.
Hypothyroid females showed significantly higher total
and LDL cholesterol (also if adjusted for lipid lowering
treatments), and were more often treated for diabetes
(Table 3).
Euthyroid, TPO-Ab positive subjects did not differ in any
examined characteristics (with the exception of the sole TPO-
Ab) from euthyroid TPO-Ab negative ones (Table 3).
Hypothyroid, TPO-Ab positive patients were further
compared with hypothyroid, TPO-Ab negative ones (data
not shown). They showed significantly higher TSH, than
hypothyroid TPO-Ab negative patients (10.3 + 3.44 vs
4.24 + 0.65 mU/L; p = 0.02 by Mann-Whitney U test); however,
they did not differ in any other examined risk factors.
Discussion
In our sample of patients with manifest coronary heart disease
we found the overall prevalence of hypothyroidism 11.5%.
It was about 4 times more prevalent in females, than in males
(23.4% vs 6.9 %, respectively). In comparison, the prevalence
of hypothyroidism in general population of the same
geographical area was found in 6.8% males and 13.8% females
(Mayer et al 2005). The review of 12 population-based studies
(Vanderpump and Tunbridge 1996) found subclinical or overt
hypothyroidism in about 5% of the general population.
Prevalence of hypothyroidism was shown to gradually
increase between age 45 and 60 years and to be higher in
females, than in males (Canaris et al 2000; Hollowell et al
2002). In contrast to these findings, the prevalence of
hypothyroidism in females was in our sample similar in both,
aged >55 or younger than 55 years. Therefore, the screening
of thyroid functions seems to be warranted in female coronary
patients without regard to age.
Hypothyroidism has been generally considered as
cardiovascular risk factor in majority of studies, mainly
because of its association with elevated serum total and
Table 2 Prevalence and odds ratio (OR) of hypothyroidism (overt or subclinical) by conventional risk factors sub-categories
Males Females
prevalence(%) OR (95% CI)
† prevalence(%) OR (95% CI)
†
Age
z <55 years 4.0 1 21.7 1
z >55 years 9.1 2.39 (0.78–7.31) 25.6 1.24 (0.41–3.78)
Smoking
z non-smokers 7.0 1 28.6 1
z smokers 8.6 1.31 (0.46–3.77)
a 12.5 2.88 (0.60–13.90)
a
Positivity of TPO-Ab
z TPO-Ab < 14 IU/L 6.3 1 16.7 1
z TPO-Ab > 14 IU/L 23.5
** 4.07 (1.17–14.10)
a 44.8
** 3.95 (1.50–10.40)
a
Elevated blood pressure
z BP < 140/90 mmHg 7.1 1 23.2 1
z BP ≥ ≥ ≥ ≥ ≥ 140/90 mmHg 7.9 1.03 (0.42–2.57)
b 25.0 0.99 (0.39–2.51)
b
Hypercholesterolemia
z TCHOL < 5 mmol/L 11.8 1 12.5 1
z TCHOL 5–6.99 mmol/L 5.5 0.41 (0.16–1.03)
c 27.1 2.87 (0.59–13.88)
c
z TCHOL ≥ ≥ ≥ ≥ ≥ 7 mmol/L 8.7 1.03 (0.42–2.57)
c 39.1 6.93 (1.02–45.20)
c
Diabetes type IId
z non-diabetic 6.6 1 22.4 1
z diabetic 9.7 1.48 (0.57–3.84)a 32.0 1.47 (0.53–4.07)a
aadjusted for age.
badjusted for age and treatment with antihypertensives.
cadjusted for age and treatment with lipid-lowering drugs.
d fasting glucose ≥ ≥ ≥ ≥ ≥ 6.8 mmol/l and/or antidiabetic treatment
*p < 0.05, 
**p < 0.01, 
***p < 0.001; differences in proportion of hypothyroidism and euthyroidism between selected subgroups (χ
2 test).
†by multiple logistic regression, presence of overt or subclinical hypothyroidism as dependent variable
Abbreviations: BP, blood presssure; CI, confidence interval; TCHOL, total cholesterol; OR, odds ratio.Vascular Health and Risk Management 2006:2(4) 503
Hypothyroidism and CHD
T
a
b
l
e
 
3
 
 
D
i
f
f
e
r
e
n
c
e
s
 
i
n
 
s
e
l
e
c
t
e
d
 
f
a
c
t
o
r
s
 
b
e
t
w
e
e
n
 
e
u
t
h
y
r
o
i
d
 
a
n
d
 
h
y
p
o
t
h
y
r
o
i
d
 
s
u
b
j
e
c
t
s
 
w
i
t
h
 
r
e
g
a
r
d
 
t
o
 
t
h
y
r
o
i
d
 
a
n
t
i
b
o
d
i
e
s
M
a
l
e
s
F
e
m
a
l
e
s
E
u
t
h
y
r
o
i
d
E
u
t
h
y
r
o
i
d
E
u
t
h
y
r
o
i
d
E
u
t
h
y
r
o
i
d
T
P
O
-
A
b
 
n
e
g
a
t
i
v
e
T
P
O
-
A
b
 
p
o
s
i
t
i
v
e
H
y
p
o
t
h
y
r
o
i
d
T
P
O
-
A
b
 
n
e
g
a
t
i
v
e
T
P
O
-
A
b
 
p
o
s
i
t
i
v
e
H
y
p
o
t
h
y
r
o
i
d
A
g
e
 
(
y
e
a
r
s
)
5
8
.
1
±
0
.
4
9
6
2
.
5
±
1
.
8
5
6
0
.
5
±
1
.
9
9
6
0
.
7
±
0
.
9
8
6
0
.
1
±
2
.
0
1
6
4
.
3
±
1
.
5
5
S
m
o
k
i
n
g
 
(
%
)
1
9
.
1
2
3
.
1
2
0
.
0
2
8
.
3
2
5
.
0
6
.
3
B
o
d
y
 
m
a
s
s
 
i
n
d
e
x
 
(
k
g
/
m
2
)
2
8
.
9
±
0
.
2
5
2
9
.
2
±
0
.
9
9
2
9
.
5
±
0
.
7
0
3
1
.
0
±
0
.
8
1
3
2
.
3
±
1
.
4
7
2
9
.
2
±
1
.
1
7
W
a
i
s
t
 
c
i
r
c
u
m
f
e
r
e
n
c
e
 
(
c
m
)
1
0
0
.
5
±
0
.
6
4
1
0
1
.
2
±
1
.
9
3
1
0
0
.
7
±
1
.
1
6
9
6
.
0
±
1
.
7
0
9
6
.
8
±
3
.
8
1
9
0
.
7
±
2
.
9
4
S
y
s
t
o
l
i
c
 
B
P
 
(
m
m
H
g
)
1
3
6
.
5
±
2
.
0
7
1
3
3
.
8
±
5
.
7
2
1
3
8
.
8
±
6
.
2
6
1
3
7
.
1
±
2
.
4
5
1
4
6
.
6
±
6
.
6
5
1
3
7
.
7
±
6
.
1
0
D
i
a
s
t
o
l
i
c
 
B
P
 
(
m
m
H
g
)
8
1
.
4
±
0
.
6
7
8
1
.
2
±
3
.
1
1
7
9
.
9
±
1
.
8
2
7
8
.
6
±
1
.
5
1
8
3
.
1
±
2
.
0
0
7
7
.
7
±
2
.
8
2
H
e
a
r
t
 
R
a
t
e
 
(
b
e
a
t
s
/
m
i
n
)
6
6
.
3
±
0
.
6
4
6
6
.
7
±
2
.
5
4
6
4
.
0
±
2
.
5
8
6
7
.
0
±
1
.
5
3
6
7
.
9
±
2
.
3
3
6
7
.
3
±
2
.
0
7
a
n
t
i
h
y
p
e
r
t
e
n
s
i
v
e
s
 
(
%
)
8
8
.
0
7
6
.
9
8
0
.
0
9
1
.
7
8
7
.
5
9
4
.
4
T
o
t
a
l
 
c
h
o
l
e
s
t
e
r
o
l
 
(
m
m
o
l
/
L
)
5
.
5
4
±
0
.
0
7
5
.
2
5
±
0
.
1
8
5
.
3
0
±
0
.
2
7
6
.
0
4
±
0
.
1
7
6
.
0
6
±
0
.
4
4
6
.
7
3
±
0
.
3
0
*
T
r
i
g
l
y
c
e
r
i
d
e
s
 
(
m
m
o
l
/
L
)
1
.
7
4
±
0
.
0
6
1
.
5
1
±
0
.
2
0
2
.
0
1
±
0
.
2
9
1
.
6
7
±
0
.
1
1
1
.
6
9
±
0
.
2
4
1
.
9
7
±
0
.
1
4
H
D
L
 
c
h
o
l
e
s
t
e
r
o
l
 
(
m
m
o
l
/
L
)
1
.
1
8
±
0
.
0
2
1
.
1
5
±
0
.
0
7
1
.
1
5
±
0
.
0
7
1
.
4
5
±
0
.
0
6
1
.
4
0
±
0
.
1
2
1
.
5
0
±
0
.
1
5
L
D
L
 
c
h
o
l
e
s
t
e
r
o
l
 
(
m
m
o
l
/
L
)
3
.
6
0
±
0
.
0
6
3
.
4
1
±
0
.
1
4
3
.
3
2
±
0
.
2
6
3
.
8
8
±
0
.
1
4
3
.
8
9
±
0
.
4
1
4
.
5
1
±
0
.
2
8
*
l
i
p
i
d
 
l
o
w
e
r
i
n
g
 
d
r
u
g
s
5
7
.
1
4
6
.
2
5
0
.
0
6
3
.
3
5
6
.
3
6
1
.
1
G
l
u
c
o
s
e
 
(
m
m
o
l
/
L
)
6
.
9
0
±
0
.
1
5
6
.
6
6
±
0
.
4
0
7
.
0
0
±
0
.
4
3
6
.
7
9
±
0
.
3
3
7
.
6
1
±
0
.
8
3
7
.
0
3
±
0
.
5
0
a
n
t
i
d
i
a
b
e
t
i
c
s
 
(
%
)
1
0
.
7
7
.
7
2
0
.
0
8
.
3
1
8
.
8
3
3
.
3
*
H
o
m
o
c
y
s
t
e
i
n
e
 
(
µ
m
o
l
/
L
)
1
3
.
4
±
0
.
3
2
1
4
.
4
±
1
.
5
3
1
7
.
9
±
4
.
5
4
*
*
1
2
.
9
±
0
.
6
5
1
2
.
9
±
1
.
0
5
1
7
.
2
±
2
.
7
0
*
*
S
e
r
u
m
 
f
o
l
a
t
e
 
(
n
g
/
m
L
)
9
.
4
1
±
1
.
7
2
7
.
1
3
±
0
.
9
0
6
.
9
8
±
0
.
5
7
7
.
2
6
±
0
.
3
1
7
.
5
2
±
0
.
4
8
6
.
7
3
±
0
.
4
4
S
e
r
u
m
 
B
1
2
 
(
p
g
/
m
L
)
3
5
0
.
0
±
1
0
.
5
3
2
9
.
5
±
4
7
.
8
3
7
8
.
6
±
4
1
.
3
3
7
5
.
4
±
2
9
.
5
3
4
0
.
9
±
3
1
.
6
3
9
0
.
3
±
4
0
.
5
u
l
t
r
a
s
e
n
s
i
t
i
v
e
 
C
R
P
 
(
m
g
/
L
)
2
.
2
8
±
0
.
1
3
2
.
4
5
±
0
.
4
2
1
.
7
5
±
0
.
3
8
2
.
6
7
±
0
.
2
9
2
.
1
0
±
0
.
4
3
1
.
7
7
±
0
.
2
8
I
C
A
M
-
1
 
(
n
g
/
m
L
)
3
0
8
.
0
±
9
.
3
2
3
5
0
.
3
±
4
2
.
9
3
6
4
.
0
±
5
7
.
7
3
5
8
.
9
±
1
9
.
4
3
7
8
.
7
±
4
7
.
3
2
9
7
.
1
±
2
7
.
7
V
C
A
M
-
1
 
(
n
g
/
m
L
)
9
2
2
.
1
±
2
9
.
1
9
7
6
.
2
±
1
4
5
.
8
1
1
8
9
.
0
±
1
5
5
.
3
*
7
7
6
.
2
±
4
6
.
1
7
1
3
.
6
±
1
2
0
.
2
7
4
3
.
7
±
6
3
.
6
v
o
n
W
i
l
l
e
b
r
a
n
d
 
f
a
c
t
o
r
 
(
%
)
1
8
7
.
7
±
4
.
9
4
1
9
3
.
1
±
1
4
.
5
2
5
1
.
5
±
3
4
.
2
*
*
1
8
7
.
2
±
9
.
8
1
1
8
8
.
8
±
2
5
.
5
1
7
0
.
3
±
1
9
.
2
T
S
H
 
(
m
l
U
/
L
)
1
.
6
5
±
0
.
0
4
1
.
7
6
±
0
.
1
7
6
.
0
5
±
1
.
4
4
*
*
*
1
.
6
5
±
0
.
1
0
2
.
0
1
±
0
.
2
1
8
.
8
2
±
3
.
0
7
*
*
*
F
r
e
e
 
t
h
y
r
o
x
i
n
e
 
(
p
m
o
l
/
L
)
1
3
.
9
±
0
.
1
6
1
3
.
7
±
0
.
3
3
1
1
.
4
±
0
.
5
2
*
*
*
1
3
.
8
±
0
.
2
6
1
3
.
9
±
0
.
5
5
1
2
.
2
±
0
.
8
4
*
*
*
T
P
O
-
A
b
 
(
I
U
/
L
)
5
.
7
2
±
0
.
1
2
1
8
6
.
7
±
8
5
.
6
*
*
*
1
3
0
.
8
±
6
5
.
4
*
*
*
5
.
7
1
±
0
.
2
6
3
2
1
.
1
±
9
8
.
6
*
*
*
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
1
6
9
.
2
±
7
4
.
2
*
*
*
*
*
*
p
 
<
 
0
.
0
0
1
,
 
*
*
 
p
 
<
 
0
.
0
1
,
 
*
p
 
<
 
0
.
0
5
,
 
a
d
j
u
s
t
e
d
 
f
o
r
 
a
g
e
.Vascular Health and Risk Management 2006:2(4) 504
Mayer et al
LDLcholesterol. Hypercholesterolemia in hypothyroidism
probably results from reduced catabolism of lipoproteins, a
phenomenon that may be explained by a decreased expression
of lipoprotein receptors (Thomson et al 1981; Scarbottolo
et al 1986). We found that females with untreated
hypothyroidism (both overt and subclinical) had
significantly higher total and LDL cholesterol. Females with
total cholesterol greater than 7 mmol/L had about a 7 times
higher risk of hypothyrodism. Surprisingly, no such
association was found in males and this discrepancy
cannot be explained by differences in lipid-lowering drug
intake.
In our study we also ascertained that females with
hypothyroidism were significantly more often treated for type
2 diabetes. Several studies found thyroid dysfunction highly
prevalent in type 1 diabetes patients; reported prevalence
was 12%–24% in females and 6% in males (Gray et al 1979;
Duckworth et al 1986; Umpierrez et al 2003). The prevalence
of thyroid dysfunction in type 2 diabetic patients (3%–6%)
was found very to be close to the estimates in the general
population. On the other hand, a recent small clinical study
reported that L-thyroxine substitution improved the ability
of insulin to stimulate glucose disposal, ie, beneficially
influenced insulin resistance, the main pathophysiological
mechanism of type 2 diabetes (Rochon et al 2003). Increased
insulin resistance in hypothyroid subjects may be the cause
of poorly compensated diabetes and consequently increased
administration of anti-diabetic drugs, as observed in the
present study.
We also found that hypothyroid males and females showed
significantly higher tHcy concentrations by about 4–5 µmol/L.
Homocysteine was established as a significant predictor of
vascular diseases. In a recent meta-analysis of 20 prospective
studies, Wald et al (2002) calculated that a 5 µmol/L increase
in tHcy raised the risk for coronary event by 32% and for
stroke by 59%. Our finding is in line with that of Christ-
Crain and colleagues (2003), who observed elevated tHcy in
patients with overt hypothyroidism, but without coronary
heart disease. The pathogenesis of elevated tHcy in
hypothyroidism is generally attributed to the reduction of
glomerular filtration rate, because of the well established
effect of hypothyroidism on the kidney (Kreisman et al 1999).
An alternative explanation of this effect could be that
concentration of tHcy can also rise through reduced activity
of methylenetetrahydrofolate reductase activity (MTHFR),
the key enzyme for re-methylation of homocysteine to
methionine. Hypothyroid individuals can be defective in
converting riboflavin to the co-enzyme flavin-adenin
dinucleotide and, consequently, deficient in MTHFR activity
(Rivlin et al 1966; Shane et al 1985; Cimino et al 1987).
The association of hypothyroidism (both overt and
subclinical) with increased uCRP levels has also been
reported (Christ-Crain et al 2003). In contrast, in our sample
we did not find any differences in uCRP or other inflammatory
markers (such as ICAM-1 and VCAM-1); these parameters
might have been influenced by concomitant therapies with
aspirin and statins.
Hypothyroidism has been observed to be associated with
endothelial dysfunction, measured by impaired endothelium-
dependent vasodilatation; it could be reversed by
L-thyroxine supplementation (Taddei et al 2004). In the
present study we used vWf as a marker of endothelial
dysfunction and it appeared significantly increased in
hypothyroid males (but not females). This association was
completely independent of other factors, which are known to
potentially impair the endothelial functions, notably from
the observed increase of tHcy.
We also examined whether autoimmune thyroid disorder
per se (TPO-Ab positivity) influenced the coronary risk
factors. Despite high prevalence of positive TPO-Ab (about
24% of males and 45% of females), no influence on any
included cardiovascular risk factor in either euthyroid or
hypothyroid subjects was found.
The question remains whether L-thyroxine
supplementation in mild hypothyroid patients could reduce
coronary risk. Several placebo-controlled randomized trials
of L-thyroxine substitution have been performed (Meier
et al 2001; Danese et al 2000; Caraccio et al 2002). Some of
these studies have shown that L-thyroxine may favorably
influence symptoms of hypothyroidism as well as
dyslipidemias. A quantitative review of 13 studies with L-
thyroxine substitution in mild thyroid failure done by Danese
et al (2000) found that the mean decrease of TCHOL was 0.20
mmol/L (with median of changes from baseline value –5%)
and mean decrease of LDL was 0.26 mmol/L, leaving HDL
cholesterol and TG uninfluenced. A recently published
population-based cohort study (Flynn et al 2006) reported,
that total mortality among patients with treated
thyroiddysfunction (hypo- or hyperthyroidism) did not differ
from rates in the general population.
The important determinant of thyroid function is current
iodine status. Because iodine supply in our population
(according to the Czech Health Statistical Yearbook, about
150 µmg/day in 2005) is within recommended limits, ourVascular Health and Risk Management 2006:2(4) 505
Hypothyroidism and CHD
patients have been assumed to have no iodine deficit. The
question remains as to what extent the thyroid parameters
were influenced by iodine-containing compounds, such as
amiodarone or contrast media. Angiography was performed
in about two-third of the patients at least 6 months before the
interview, when the thyroid parameters were estimated. It
was proved that application of iodine contrast media leads to
a small but significant decrease in fT4 and an increase in
TSH. The peak of this effect is on day 3 and depends on pre-
existing thyroid status (Gartner et al 2004). The long-term
effect on thyroid status remains questionable. In addition,
10 patients in our sample were being treated with amiodarone.
Four showed increased fT4 and could be misclassified as
hyperthyroid; however amiodarone treatment did not
influence the prevalence of hypothyroidism.
There are several limitations of this study. Because of
the cross-sectional design, it is impossible to consider the
causality of hypothyroidism in coronary heart disease
etiology. We also have no evidence as to whether thyroid
dysfunction appeared before the coronary event or in the
first months thereafter. Only patients surviving the acute
coronary event for least 6 months were included according
to the protocol; the prevalence of hypothyroidism can be
potentially underestimated by this bias. Finally, the
definition of thyroid function categories was based on
single laboratory estimation, while from clinical point of
view, it is necessary to confirm the diagnosis by repeated
measurements.
In conclusion, thyroid dysfunction has to be considered
a highly prevalent condition, mainly in females, which could
potentially contribute to the overall coronary risk and may
be amenable to secondary preventive intervention. The
evidence of benefit of L-thyroxine substitution in addition
to conventional therapies on morbidity and mortality of
coronary patients remains to be elucidated by randomized
pharmacological trials.
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